Scribd Logo
Upload

Welcome to Scribd!

  • 37 views

    Abstract 1

    Uploaded by

    Wobik Hope
    An abstract by Kibow titled “PROGRESS IN DEVISING A BOWEL BASED PROBIOTIC THERAPY FOR UREMIA. ” was presented at the 5th annual meeting in “prevention in Renal Disease”, Sep 2006, Toronto, Canada (Section 11, Abs 18, 2006). The abstract’s objective is to throw some light on how probiotics are helpful for enhancing gut health by supplying good probiotic bacteria and therefore reduces the chances of Kidney issues like Chronic Kidney Disease. The abstract talks about the medical trials that were performed and the prerequisites of the trials that were initiated so that the test results come out clearer for drawing conclusions.

    Copyright:

    © All Rights Reserved

    Abstract 1

    Uploaded by

    Wobik Hope
    37 views2 pages
    An abstract by Kibow titled “PROGRESS IN DEVISING A BOWEL BASED PROBIOTIC THERAPY FOR UREMIA. ” was presented at the 5th annual meeting in “prevention in Renal Disease”, Sep 2006, Toronto, Canada (Section 11, Abs 18, 2006). The abstract’s objective is to throw some light on how probiotics are helpful for enhancing gut health by supplying good probiotic bacteria and therefore reduces the chances of Kidney issues like Chronic Kidney Disease. The abstract talks about the medical trials that were performed and the prerequisites of the trials that were initiated so that the test results come out clearer for drawing conclusions.

    Copyright

    © © All Rights Reserved

    Did you find this document useful?

    Is this content inappropriate?

    An abstract by Kibow titled “PROGRESS IN DEVISING A BOWEL BASED PROBIOTIC THERAPY FOR UREMIA. ” was presented at the 5th annual meeting in “prevention in Renal Disease”, Sep 2006, Toronto, Canada (Section 11, Abs 18, 2006). The abstract’s objective is to throw some light on how probiotics are helpful for enhancing gut health by supplying good probiotic bacteria and therefore reduces the chances of Kidney issues like Chronic Kidney Disease. The abstract talks about the medical trials that were performed and the prerequisites of the trials that were initiated so that the test results come out clearer for drawing conclusions.

    Copyright:

    © All Rights Reserved
    37 views2 pages

    Abstract 1

    Uploaded by

    Wobik Hope
    An abstract by Kibow titled “PROGRESS IN DEVISING A BOWEL BASED PROBIOTIC THERAPY FOR UREMIA. ” was presented at the 5th annual meeting in “prevention in Renal Disease”, Sep 2006, Toronto, Canada (Section 11, Abs 18, 2006). The abstract’s objective is to throw some light on how probiotics are helpful for enhancing gut health by supplying good probiotic bacteria and therefore reduces the chances of Kidney issues like Chronic Kidney Disease. The abstract talks about the medical trials that were performed and the prerequisites of the trials that were initiated so that the test results come out clearer for drawing conclusions.

    Copyright:

    © All Rights Reserved
    of 2

    This oral presentation made at the 5th annual meeting in “prevention in

    Renal Disease”, Sep, 2006, Toronto, Canada (Section 11, Abs 18, 2006)

    Title: PROGRESS IN DEVISING A BOWEL BASED PROBIOTIC


    THERAPY FOR UREMIA.

    Natarajan Ranganathan, Ph D1, Beena G Patel, Ph D1, Pari Ranganathan, MSMTASCP1, Rahul
    Dheer, BS1, Richard Palmquist, DVM2 and Gary Van Engelenberg, DVM, CVA3. Eli A
    Friedman, M.D.4 1
    Kibow Biotech Inc, Newtown Square,, PA, United States; 2Centinela
    Animal Hospital, Inglewood, CA, United States; 3Iowa Veterinary Acupuncture Clinic, C Des
    Moines, IA, United States and 4 Downstate Medical Center, State University of New York
    (SUNY), Brooklyn, NY, United States.

    To assess the potential of devising a gut-based probiotic formulation as


    therapy in chronic kidney disease (CKD), we have performed extensive in
    vitro R&D investigations in our labs. We then used the Simulated Human
    Intestinal Microbial Ecosystem (SHIME, Ghent University, Belgium), a
    computer controlled gastrointestinal in vitro simulated system and validated
    the ability of the microbial formulation to metabolize and thus reduce the
    concentration of nitrogenous components including urea, creatinine, and uric
    acid. Bacterial strains studied were Streptococcus thermophilus (St),
    Lactobacillus acidophilus (La) and Bifidobacterium longum (Bl). We then
    confirmed and reported that these bacterial formulations, fed orally in 5/6th
    nephrectomized rodent - rat (at Thomas Jefferson University, Philadelphia,
    PA) and minipig models (at Indiana University, Indianapolis, IN), reduced
    both blood urea nitrogen (BUN) and serum creatinine (Scr) levels.

    Before starting human trials we conducted a study of the effect of our


    probiotic mixture in clinical renal failure in veterinary practice. Two
    independent veterinarians initiated trials of Kibow Biotics® in uremic cats
    and dogs of both genders and varying body weights. Treatment consisted of
    orally ingesting live bacteria (expressed as Colony Forming Units – CFU) as
    enterically coated gel caps (15 billion CFU/gel cap) administered twice or
    thrice daily for a total dose 30 to 45 billion CFU per day (because of
    difficulties in feeding the whole gel cap to some of the smaller animals, a few
    pet owners broke the gel cap and mixed the contents with their animal
    feed). Study animals were solicited from their owners after a clear
    explanation that the probiotic given had not previously been tested in a
    clinical setting.

    Azotemia declined during therapy; in cats (n=7), BUN fell from 54 13.0 to
    45.1+12.0 mg/dl, while Scr decreased from 4.0 1.9 to 2.9 0.7 mg/dl.
    Similar results were obtained in dogs (n=6), BUN decreased from 64.7 35.4
    to 30.4 17.7 mg/dl, while Scr fell from 2.6 1.3 to 2.0 1.5 mg/dl. No adverse
    effects were noted during 2-6 months of treatment. Survey questionnaires
    sent to pet owners generated strongly positive results from the respondents,
    who reported either significant improvement in uremia marker values or, in
    more advanced cases of kidney failure, stabilization and improved quality of
    life for their companion animals. These data are presented as a step in the
    evolution of a gut-based uremia therapy with possible application in human
    patients.

    Our data support the view that testing efficacy of orally administered
    probiotics in a clinical veterinary practice setting affords a rational
    opportunity to confirm and validate inferences drawn from partially
    nephrectomized test animals. A safety study in healthy volunteers has also
    been accomplished with Kibow Biotics® (identical product formulation as
    used in cats and dogs with renal failure) by our own group of volunteer
    employees with required legal documentation. The next step is the initiation
    of pilot scale human clinical trials in stage III and IV CKD patients. Efforts
    are in progress towards accomplishing this goal in several countries.

    You might also like